Loteprednol Etabonate Suspension Eye Drops (Lotemax) is a glucocorticoid ophthalmic preparation.
How to Use Loteprednol Etabonate Suspension Eye Drops (Lotemax)
Routine Dosage
Adults and Adolescents (≥12 years old): Instill 1 drop into the conjunctival sac, 4 times a day.
For severe inflammation: The dosage can be increased to 1 drop per hour; gradually reduce the frequency after the condition improves.
Postoperative anti-inflammation: Start using 24 hours before surgery and continue for 2 weeks after surgery.
Key Points for Administration
Shake well before use: Shake the suspension thoroughly for 10 seconds to ensure uniform distribution of the drug.
Avoid contamination: Do not let the bottle tip touch the eyelids or eyelashes when instilling drops; tightly close the bottle cap immediately after use.
Interval for combined medication: If other eye drops need to be used, allow an interval of at least 5 minutes between administrations.
Dose Adjustment and Contraindications of Loteprednol Etabonate Suspension Eye Drops (Lotemax)
Circumstances Requiring Dose Adjustment
Long-term use: If the medication is used for more than 10 days, intraocular pressure should be evaluated. If increased intraocular pressure (steroid-induced glaucoma) occurs, the dose should be gradually reduced or the drug discontinued.
Insufficient efficacy: If there is no improvement in symptoms 72 hours after medication, the diagnosis needs to be re-evaluated.
Absolute Contraindications
Contraindicated in patients allergic to loteprednol etabonate or excipients in the preparation (e.g., benzalkonium chloride).
Contraindicated in patients with active ocular viral infections (e.g., herpetic keratitis), fungal infections, or purulent infections.
Precautions for Use
Patients with thin corneas: May delay wound healing; close monitoring is required.
Patients with a history of glaucoma: Even short-term use may induce increased intraocular pressure.
Medication for Special Populations of Loteprednol Etabonate Suspension Eye Drops (Lotemax)
Pediatric Patients
Children <12 years old: Efficacy has not been fully established; use with caution after weighing the pros and cons.
Premature infants: Contraindicated, as the benzalkonium chloride preservative may cause corneal toxicity.
Pregnancy and Lactation
Pregnancy: Animal studies show a low risk, but human data are limited; it is recommended to use only when clearly necessary.
Lactation: Systemic absorption of topically administered medication is minimal, but avoid pressing the lacrimal sac area after instillation to reduce absorption.
Geriatric Patients
No dose adjustment is required, but enhanced monitoring is needed for those with concurrent glaucoma or cataracts.


